FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:WDR59-KIFC3

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: WDR59-KIFC3
FusionPDB ID: 99036
FusionGDB2.0 ID: 99036
HgeneTgene
Gene symbol

WDR59

KIFC3

Gene ID

79726

3801

Gene nameWD repeat domain 59kinesin family member C3
SynonymsCDW12|FP977|p90-120-
Cytomap

16q23.1

16q21

Type of geneprotein-codingprotein-coding
DescriptionGATOR complex protein WDR59CDw12 antigenWD repeat-containing protein 59kinesin-like protein KIFC3
Modification date2020031320200327
UniProtAcc.

Q9BVG8

Main function of 5'-partner protein: FUNCTION: Minus-end microtubule-dependent motor protein. Involved in apically targeted transport (By similarity). Required for zonula adherens maintenance. {ECO:0000250, ECO:0000269|PubMed:19041755}.
Ensembl transtripts involved in fusion geneENST idsENST00000262144, ENST00000562331, 
ENST00000566975, ENST00000379655, 
ENST00000421376, ENST00000445690, 
ENST00000465878, ENST00000539578, 
ENST00000540079, ENST00000541240, 
ENST00000543930, ENST00000562903, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score14 X 10 X 10=14006 X 6 X 3=108
# samples 175
** MAII scorelog2(17/1400*10)=-3.04182017569463
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(5/108*10)=-1.11103131238874
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: WDR59 [Title/Abstract] AND KIFC3 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: WDR59 [Title/Abstract] AND KIFC3 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)WDR59(75018862)-KIFC3(57795083), # samples:3
Anticipated loss of major functional domain due to fusion event.WDR59-KIFC3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
WDR59-KIFC3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
WDR59-KIFC3 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
WDR59-KIFC3 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr16:75018862/chr16:57795083)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across WDR59 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across KIFC3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000262144WDR59chr1675018862-ENST00000465878KIFC3chr1657795083-1511185131793220
ENST00000262144WDR59chr1675018862-ENST00000379655KIFC3chr1657795083-1482185131814227
ENST00000262144WDR59chr1675018862-ENST00000445690KIFC3chr1657795083-1509185131793220
ENST00000262144WDR59chr1675018862-ENST00000421376KIFC3chr1657795083-1300185131793220
ENST00000262144WDR59chr1675018862-ENST00000541240KIFC3chr1657795083-1283185131793220
ENST00000262144WDR59chr1675018862-ENST00000540079KIFC3chr1657795083-1269185131793220
ENST00000262144WDR59chr1675018862-ENST00000543930KIFC3chr1657795083-1196185131793220
ENST00000262144WDR59chr1675018862-ENST00000562903KIFC3chr1657795083-1008185131793220
ENST00000262144WDR59chr1675018862-ENST00000539578KIFC3chr1657795083-903185131793220

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000262144ENST00000465878WDR59chr1675018862-KIFC3chr1657795083-0.147654440.8523456
ENST00000262144ENST00000379655WDR59chr1675018862-KIFC3chr1657795083-0.187838990.812161
ENST00000262144ENST00000445690WDR59chr1675018862-KIFC3chr1657795083-0.148121550.85187846
ENST00000262144ENST00000421376WDR59chr1675018862-KIFC3chr1657795083-0.117698440.8823015
ENST00000262144ENST00000541240WDR59chr1675018862-KIFC3chr1657795083-0.1168701350.8831299
ENST00000262144ENST00000540079WDR59chr1675018862-KIFC3chr1657795083-0.1159166840.88408333
ENST00000262144ENST00000543930WDR59chr1675018862-KIFC3chr1657795083-0.113414130.8865859
ENST00000262144ENST00000562903WDR59chr1675018862-KIFC3chr1657795083-0.116779120.8832209
ENST00000262144ENST00000539578WDR59chr1675018862-KIFC3chr1657795083-0.097578020.902422

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for WDR59-KIFC3

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
WDR59chr1675018862KIFC3chr165779508318517WSSENVVVEFRDSQVFEFGHTNRTTE

Top

Potential FusionNeoAntigen Information of WDR59-KIFC3 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
WDR59-KIFC3_75018862_57795083.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
WDR59-KIFC3chr1675018862chr1657795083185HLA-B27:04FRDSQVFEF0.99870.5983918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B27:05FRDSQVFEF0.99850.7252918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:03VEFRDSQVF0.9950.7867716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B39:01FRDSQVFEF0.9940.6823918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B13:01VEFRDSQVF0.9920.6565716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B39:06FRDSQVFEF0.99130.5771918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B38:01FRDSQVFEF0.99040.7843918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B18:01VEFRDSQVF0.98950.8274716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B38:02FRDSQVFEF0.98930.7742918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B15:18FRDSQVFEF0.95490.6162918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B15:37FRDSQVFEF0.82480.5363918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B15:03VEFRDSQVF0.43430.5805716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B39:13VEFRDSQVF0.19620.8462716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:03VVEFRDSQVF0.76990.7584616
WDR59-KIFC3chr1675018862chr1657795083185HLA-B38:01EFRDSQVFEF0.64670.8605818
WDR59-KIFC3chr1675018862chr1657795083185HLA-B38:02EFRDSQVFEF0.57140.8785818
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:03VEFRDSQVFEF0.99810.8681718
WDR59-KIFC3chr1675018862chr1657795083185HLA-C03:14FRDSQVFEF0.99910.9481918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:27FRDSQVFEF0.99890.8949918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:95FRDSQVFEF0.99870.5186918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:05FRDSQVFEF0.99860.9122918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:29FRDSQVFEF0.99850.8215918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B27:14FRDSQVFEF0.99850.6198918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C04:10FRDSQVFEF0.99710.7347918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C04:07FRDSQVFEF0.9970.7255918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:13FRDSQVFEF0.99650.85918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B39:12FRDSQVFEF0.99470.6926918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B39:05FRDSQVFEF0.9890.6673918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:80FRDSQVFEF0.98440.8767918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:67FRDSQVFEF0.98440.8767918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:19FRDSQVFEF0.98320.5508918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:10FRDSQVFEF0.96740.9137918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:46FRDSQVFEF0.96340.7411918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B27:03FRDSQVFEF0.87590.7566918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C04:06FRDSQVFEF0.84040.6786918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B73:01FRDSQVFEF0.82040.5026918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B15:21FRDSQVFEF0.76360.8317918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B14:03FRDSQVFEF0.63920.5874918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C04:14FRDSQVFEF0.63260.7166918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B39:08VEFRDSQVF0.48950.7955716
WDR59-KIFC3chr1675018862chr1657795083185HLA-C12:16FRDSQVFEF0.32670.9503918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B27:06FRDSQVFEF0.9990.5949918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B27:08FRDSQVFEF0.99870.5726918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B27:10FRDSQVFEF0.99860.755918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B27:09FRDSQVFEF0.99770.6682918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C04:03FRDSQVFEF0.99770.7613918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C04:01FRDSQVFEF0.9970.7255918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B40:04VEFRDSQVF0.99590.5049716
WDR59-KIFC3chr1675018862chr1657795083185HLA-C18:01FRDSQVFEF0.99520.7561918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B39:02FRDSQVFEF0.99510.7238918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:07VEFRDSQVF0.9950.7867716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:26VEFRDSQVF0.9950.7867716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:13VEFRDSQVF0.9950.7867716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B39:31FRDSQVFEF0.99430.6851918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:17FRDSQVFEF0.99310.9268918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B18:04VEFRDSQVF0.99220.8444716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B18:08VEFRDSQVF0.99060.7263716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B18:07VEFRDSQVF0.99060.7972716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B38:05FRDSQVFEF0.99040.7843918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B18:05VEFRDSQVF0.98950.8274716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B18:06VEFRDSQVF0.98840.8166716
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:02FRDSQVFEF0.98440.8767918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B48:02FRDSQVFEF0.97980.8561918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B18:03VEFRDSQVF0.96120.8203716
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:22FRDSQVFEF0.94330.5783918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C03:67FRDSQVFEF0.94290.9604918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C07:04FRDSQVFEF0.93250.8842918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B39:11FRDSQVFEF0.88460.5766918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B18:11VEFRDSQVF0.87760.6907716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B15:53VEFRDSQVF0.87040.6994716
WDR59-KIFC3chr1675018862chr1657795083185HLA-C04:04FRDSQVFEF0.82250.6566918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B15:12VEFRDSQVF0.80240.7457716
WDR59-KIFC3chr1675018862chr1657795083185HLA-C06:06FRDSQVFEF0.75550.9879918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C06:08FRDSQVFEF0.74650.9788918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B15:54VEFRDSQVF0.62480.6786716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B35:28VEFRDSQVF0.51730.8143716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B35:20VEFRDSQVF0.50640.8312716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B48:02VEFRDSQVF0.30930.7695716
WDR59-KIFC3chr1675018862chr1657795083185HLA-C06:02FRDSQVFEF0.26290.9847918
WDR59-KIFC3chr1675018862chr1657795083185HLA-C06:17FRDSQVFEF0.26290.9847918
WDR59-KIFC3chr1675018862chr1657795083185HLA-B39:02VEFRDSQVF0.19530.844716
WDR59-KIFC3chr1675018862chr1657795083185HLA-B15:53VVEFRDSQVF0.98240.7641616
WDR59-KIFC3chr1675018862chr1657795083185HLA-B48:02VVEFRDSQVF0.95420.7803616
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:07VVEFRDSQVF0.76990.7584616
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:26VVEFRDSQVF0.76990.7584616
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:13VVEFRDSQVF0.76990.7584616
WDR59-KIFC3chr1675018862chr1657795083185HLA-B38:05EFRDSQVFEF0.64670.8605818
WDR59-KIFC3chr1675018862chr1657795083185HLA-B18:11VVEFRDSQVF0.6180.7739616
WDR59-KIFC3chr1675018862chr1657795083185HLA-B15:53VEFRDSQVFEF0.99840.7244718
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:13VEFRDSQVFEF0.99810.8681718
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:07VEFRDSQVFEF0.99810.8681718
WDR59-KIFC3chr1675018862chr1657795083185HLA-B44:26VEFRDSQVFEF0.99810.8681718
WDR59-KIFC3chr1675018862chr1657795083185HLA-B48:02VEFRDSQVFEF0.98080.7472718

Top

Potential FusionNeoAntigen Information of WDR59-KIFC3 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
WDR59-KIFC3_75018862_57795083.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
WDR59-KIFC3chr1675018862chr1657795083185DRB1-0904VVEFRDSQVFEFGHT621
WDR59-KIFC3chr1675018862chr1657795083185DRB1-0904VVVEFRDSQVFEFGH520
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1501ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1505ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1506ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1507SENVVVEFRDSQVFE217
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1507ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1509ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1512SENVVVEFRDSQVFE217
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1512ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1513ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1516ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1520ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1522ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1524ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1532ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1533ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1535ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1535SENVVVEFRDSQVFE217
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1536ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1536SENVVVEFRDSQVFE217
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1540ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1541ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1542ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1543ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1545ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1546ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1548SENVVVEFRDSQVFE217
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1548ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1549ENVVVEFRDSQVFEF318
WDR59-KIFC3chr1675018862chr1657795083185DRB1-1549SENVVVEFRDSQVFE217

Top

Fusion breakpoint peptide structures of WDR59-KIFC3

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10349VVEFRDSQVFEFGHWDR59KIFC3chr1675018862chr1657795083185

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of WDR59-KIFC3

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN10349VVEFRDSQVFEFGH-7.15543-7.26883
HLA-B14:023BVN10349VVEFRDSQVFEFGH-4.77435-5.80965
HLA-B52:013W3910349VVEFRDSQVFEFGH-6.80875-6.92215
HLA-B52:013W3910349VVEFRDSQVFEFGH-4.20386-5.23916
HLA-A11:014UQ210349VVEFRDSQVFEFGH-7.5194-8.5547
HLA-A11:014UQ210349VVEFRDSQVFEFGH-6.9601-7.0735
HLA-A24:025HGA10349VVEFRDSQVFEFGH-7.52403-7.63743
HLA-A24:025HGA10349VVEFRDSQVFEFGH-5.82433-6.85963
HLA-B27:056PYJ10349VVEFRDSQVFEFGH-3.28285-4.31815
HLA-B44:053DX810349VVEFRDSQVFEFGH-5.91172-6.94702
HLA-B44:053DX810349VVEFRDSQVFEFGH-4.24346-4.35686
HLA-B35:011A1N10349VVEFRDSQVFEFGH-5.9251-6.0385
HLA-B35:011A1N10349VVEFRDSQVFEFGH-4.80237-5.83767

Top

Vaccine Design for the FusionNeoAntigens of WDR59-KIFC3

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
WDR59-KIFC3chr1675018862chr1657795083616VVEFRDSQVFGTAGAGTTCCGTGACTCCCAGGTGTTTGAG
WDR59-KIFC3chr1675018862chr1657795083716VEFRDSQVFGAGTTCCGTGACTCCCAGGTGTTTGAG
WDR59-KIFC3chr1675018862chr1657795083718VEFRDSQVFEFGAGTTCCGTGACTCCCAGGTGTTTGAGTTTGGC
WDR59-KIFC3chr1675018862chr1657795083818EFRDSQVFEFTTCCGTGACTCCCAGGTGTTTGAGTTTGGC
WDR59-KIFC3chr1675018862chr1657795083918FRDSQVFEFCGTGACTCCCAGGTGTTTGAGTTTGGC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
WDR59-KIFC3chr1675018862chr1657795083217SENVVVEFRDSQVFEGAAAACGTGGTTGTAGAGTTCCGTGACTCCCAGGTGTTTGAGTTT
WDR59-KIFC3chr1675018862chr1657795083318ENVVVEFRDSQVFEFAACGTGGTTGTAGAGTTCCGTGACTCCCAGGTGTTTGAGTTTGGC
WDR59-KIFC3chr1675018862chr1657795083520VVVEFRDSQVFEFGHGTTGTAGAGTTCCGTGACTCCCAGGTGTTTGAGTTTGGCCACACT
WDR59-KIFC3chr1675018862chr1657795083621VVEFRDSQVFEFGHTGTAGAGTTCCGTGACTCCCAGGTGTTTGAGTTTGGCCACACTAAT

Top

Information of the samples that have these potential fusion neoantigens of WDR59-KIFC3

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SKCMWDR59-KIFC3chr1675018862ENST00000262144chr1657795083ENST00000379655TCGA-EE-A2MN-06A

Top

Potential target of CAR-T therapy development for WDR59-KIFC3

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to WDR59-KIFC3

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to WDR59-KIFC3

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource